Featured FDA Approves Finerenone for HF Patients With Mildly Reduced or Preserved EF The agency’s decision, based on FINEARTS-HF, extends the option for MRA-based therapy beyond patients with reduced LVEF. By Caitlin E. Cox July 14, 2025